Sanofi’s Rilzabrutinib Gets EU Orphan Drug Status for IgG4-Related Disease
Paris, August 14, 2025 – The European Medicines Agency (EMA) has granted orphan drug designation to Sanofi’s rilzabrutinib, a...
Vaccines, Blood & Biologics
Sanofi Strengthens Vaccine Pipeline with Acquisition of Vicebio
Paris, France — August 21, 2025 – Sanofi has announced the acquisition of Vicebio, a biotechnology company specializing in...
mRNA Patent Dispute Resolved: BioNTech, CureVac, and GSK Strike $370M Licensing Deal
August 8, 2025 — London, UK. BioNTech SE has reached an agreement with CureVac to receive a non-exclusive license...
Bio-Thera and STADA Expand Alliance with Biosimilars-Tocilizumab
August 22, 2025 — Bio-Thera Solutions and STADA Arzneimittel have announced the expansion of their biosimilars partnership to include...
FDA Approves Precigen’s PAPZIMEOS, First Immunotherapy for Recurrent Respiratory Papillomatosis
August 19, 2025 — Germantown, MD – Precigen, Inc. (NASDAQ: PGEN) today announced that the U.S. Food and Drug...
Eli Lilly $1.3B Collaboration with Boston based Superluminal to develop Small Molecule Therapy for Cardiometabolic and Obesity.
Boston, MA – August 14, 2025 – Superluminal Medicines, a pioneering drug discovery company integrating artificial intelligence, machine learning,...
Strand Therapeutics Secures $153M for mRNA Technology
By NewsDesk — Aug. 7, 2025 (America/New York) Strand Therapeutics, a Boston‑based startup pioneering programmable messenger RNA (mRNA) therapies, closed a $153 million Series B...
FDA Grants Accelerated Approval for EMRELIS™ (telisotuzumab) in Advanced NSCLC With High c-Met Overexpression
NORTH CHICAGO, Ill., May 14, 2025 — AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration...